Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved commercial production at the company’s newest cell therapy manufacturing facility in Devens, Massachusetts. The Devens site is a critical component of BMS’ expanding global cell therapy manufacturing footprint for long-term supply of the company’s cell therapy portfolio.

Bristol Myers Squibb is a 2022 Tax Incentive awardee. This program provides incentives to companies, of all sizes, looking to expand their efforts by creating new, long-term jobs in Massachusetts. Bristol Myers Squibb is also a sponsor of the MLSC’s Massachusetts Next Generation (MassNextGen) Initiative that aims to support a broad network of underrepresented entrepreneurs through funding, coaching, and network building.